To receive daily emails from Breaking Christian News to your inbox CLICK HERE


SHARE THIS ARTICLE Printer friendly version of this page

New Pill Combo Cures 9 out of 10 Hepatitis C Patients in 12 Weeks

Rosanne Fohn-News Release : Jul 30, 2014  University of Texas Health Science Center

"We are now in the midst of a paradigm shift of moving away from complicated injection regimens that included interferon and often caused significant side effects with modest success rates." -Dr. Eric Lawitz

Dr. LAwitz(San Antonio, TX)—Researchers from The University of Texas Health Science Center at San Antonio, the Texas Liver Institute and other institutions have identified a combination of pills that cures 9 of 10 hepatitis C patients. (Photo: uthscsa.edu)

The combination of the drugs sofosbuvir and simeprevir, with or without ribavirin, cured 93 percent of patients in 12 weeks, and was well tolerated by patients, according to the study published in The Lancet this month.

Eric Lawitz, M.D., clinical professor in the School of Medicine at the UT Health Science Center and vice president of research and scientific development at the Texas Liver Institute, led the clinical trial conducted in the United States.

News of this study is important because encouraging people to take a simple blood test to diagnose hepatitis C could result in their being treated with an oral regimen that could prevent serious liver diseases such as cancer, cirrhosis or liver failure. Hepatitis C is the leading cause of liver transplants in the US today.

Hep CIt is estimated that 3.2 million people in the U.S. have hepatitis C and most do not know they are infected. Historically, cure rates for hepatitis C patients with cirrhosis have been lower than 50 percent and the treatment has had numerous adverse effects. The previous standard of care with interferon involved a complicated regimen of shots and up to 18 tablets a day for up to 48 weeks, and subsequent six months of follow-up care to determine if the therapy was successful. There were also major side effects with the treatment, including rash, anemia and depression.

"We are now in the midst of a paradigm shift of moving away from complicated injection regimens that included interferon and often caused significant side effects with modest success rates," Dr. Lawitz said. "This trial provides a glimpse into the outcomes of sofosbuvir and simeprevir for treatment of hepatitis C. Both drugs are approved by the FDA but are not yet approved together for this treatment," he said.

All-oral regimens hold promise for a hepatitis C cure rate of more than 90 percent of patients, including those with liver cirrhosis (liver scarring). Participants in the study had the most common form of hepatitis C (genotype 1) and were difficult to treat due to either failing a previous course of interferon and ribavirin, or having cirrhosis.

More than 150 million people worldwide have chronic hepatitis C, a major cause of liver cirrhosis and liver cancer, with 350,000 to 500,000 deaths reported annually.







SHARE THIS ARTICLE Printer friendly version of this page

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Other Recent Articles from Breaking Christian News

West Virginia Student Helps Pass Bill to Teach Intelligent Design: 'This Is a God-Fearing State'

Free Speech Resolution Allows Satanic Temple 'Invocation' Sparking Chaos at a Michigan Board Meeting

Paris Olympics Will Feature a 'Pride House' to 'Celebrate' Homosexual and Gender-Confused Athletes

Video Captures Drag Queen Indoctrinating Kids, Getting Them to Chant... 'Free Palestine'

Who's Funding the Anti-Israel, Pro-Palestine Protests?

More Lawfare: Former Arizona GOP Chair Kelli Ward, Rudy Giuliani, Mark Meadows Indicted for Role in Alternate Electors Case

DEVELOPING: Harvey Weinstein Rape Conviction Overturned By New York Appellate Court

Supreme Court Puts Final Nail in Coffin of Effort to Block Trump from Ballot in Arizona

SCOTUS Begins Hearing Arguments on Presidential Immunity: Is This the Most Important Day for Donald Trump?

Courageous: Worship Leader Sean Feucht Prepares to Confront Anti-Israel Evil, Darkness, and Horror

'Australian Censorship Commissar' Orders X to Globally Remove Video of Islamic Terror Attack on Christian Bishop

New Emails Expose Biden's Connection to Whistleblower Who Got Trump Impeached

Tennessee Passes Bill Letting Teachers Carry Guns at Schools

Transgender Movement Is Losing Its Influence on Social Media to Shut Down Debate

Ohio Attorney General Breaks Down Leftist Legal 'Trick' to Block GOP Efforts to Protect Kids

Nearly 2,000 Minnesota Students, 15 Teachers Walk Out of LGBTQ 'Indoctrination' Lesson

Pro-Life Advocates to Hold Prayer and Worship Service at the United States Supreme Court on the Eve of 'Idaho v. United States' Abortion Case

'Just a Disaster': Biden's Title IX Rule Empowers LGBTQ Movement, Erases Women and Justice

WATCH: Brave School Girl Reveals in Graphic Detail How TRANS Student Savagely Assaulted Her Friend While Blasting Woke School Officials for Letting it Happen

United For Israel March Happening on the Columbia University Campus, April 25th



Search the Articles Archives

Keyword:  
Author:  
Words Posted On:  
Day Month Year



BCN Plus

Follow BCN on Twitter
Are You Praying for Our Government Leaders?
BCN Staff

Steve Shultz
Steve Shultz, Managing Editor
Founder and Owner


Aimee Herd
Aimee Herd, Editor


BCN Plus
Are You Praying for President Trump?
 
 

All articles on this site and emails from BCN are copyrighted property of Breaking Christian News. Permission is given to link to, or share a BCN story if proper attribution is given to both the original writer and summarizer of the story. Breaking Christian News 2005-2019. All Rights Reserved.


Breaking Christian News is a division of Elijah List Publications, Inc. All Rights Reserved


Disclaimer: Articles and links, as well as the source articles linked to; do not necessarily reflect the opinion of Breaking Christian News.

editor@breakingchristiannews.com